1. Scrip
  2. >>Business

J&J’s Spravato On Track To Be A Blockbuster, Five Years In

 
• By Jessica Merrill

 Johnson & Johnson’s drug for treatment-resistant depression got off to a slow start when it launched in 2019, but strong sales growth has put it on a blockbuster trajectory this year. 

blockbuster
Spravato is on track to become a blockbuster seller • Source: Shutterstock

It took some time but Johnson & Johnson’s Spravato (esketamine), a nasal spray approved for treatment-resistant depression in 2019, is poised to become a blockbuster seller this year. J&J reported second quarter financial results on 17 July, with Spravato being one of 10 drugs in the innovative medicines portfolio that turned in double-digit growth.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Business

Biotech Leaders Fear FDA Disruption Is Causing Delays

 
• By Jessica Merrill

A letter to US Senate HELP Committee Chair Bill Cassiday sounds an alarm about irreparable damage to the FDA, signed by more than 200 biotech executives and investors.

Ferring’s Faith In Bladder Cancer Gene Therapy Starts To Pay Off

 
• By Kevin Grogan

Adstiladrin sales hit €70m in first full year on the market

Q1 VC Financings Fall Short As Early Deals, Mega-Rounds Dip

 
• By Mandy Jackson

Evaluate data show that biopharma companies raising cash in the smallest and largest categories of venture capital financings struggled to meet bars set in prior quarters.